FILTER

Refine your search with the following facets to narrow down your results.

4 Current news of corat-therapeutics

image description

Drug manufacturer Dermapharm invests millions in CORAT Therapeutics

Further development of the SARS-CoV-2 antibody COR-101, which is currently in the clinical phase

13-Jul-2021 - For the fast and efficient delivery of its innovative drug COR 101 against COVID-19, CORAT Therapeutics GmbH announces the partnership with Dermapharm Holding SE, a manufacturer of branded pharmaceuticals. The partnership is intended to accelerate clinical development and facilitate the expansion ...

antibodies coronaviruses Covid-19 +1
image description

CORAT antibody recognizes aggressive “delta” variant

COR-101 binds and inhibits all B.1.617 SARS-CoV-2 variants

24-Jun-2021 - CORAT Therapeutics GmbH announced that its COR-101 antibody, currently in Phase Ib/II clinical trials against SARS-CoV-2, recognizes the latest aggressive “delta“ variant B.1.617.2. "COR-101 is under evaluation in hospitalized COVID-19 patients with moderate to severe symptoms. In this affected ...

antibodies coronaviruses Covid-19 +1
image description

CORAT Therapeutics obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101

COR-101 is a human antibody that blocks virus infection by binding to the spike protein

17-Mar-2021 - CORAT Therapeutics GmbH obtained the regulatory approval as well as the favorable opinion from the central ethics committee to conduct the clinical phase Ib/II trial with its antibody COR-101 against COVID-19. COR-101 is a neutralizing human antibody that binds to the receptor binding domain ...

antibodies antibody therapy coronaviruses +3
image description

Human antibody against COVID-19 ready for clinical trials

Antibody blocks the cell entry of SARS-CoV-2 and thus prevents the proliferation of corona viruses

20-Nov-2020 - CORAT Therapeutics CEO Dr. Andreas Herrmann announced the completion of the production campaign of the first major batch of COR-101, which is now available for clinical trials. COR-101 is a fully human antibody developed in Braunschweig, Germany, which efficiently blocks the cell entry of ...

antibodies coronaviruses Covid-19 +1